title: The prognostic value of UHRF-1 and p53 in gastric cancer.
abstract: OBJECTIVE
  This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer.
  
  
  METHODS
  Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) were evaluated. Immunohistochemistry was used to examine expression of UHRF-1 and p53 in gastric cancers and a control group diagnosed with gastritis.
  
  
  RESULTS
  The median age was 63 years (18-83 years) in the study group. UHRF-1 was positive in 15 (23%) patients with gastric cancer and fi ve (21.7%) patients with gastritis (P = 0.559). UHRF1 expression level in gastric cancer is more powerful than in gastritis (P = 0.046). Thirty-seven (61%) patients with gastric cancer and only one patient with gastritis were p53 positive (P < 0.001). After a median follow-up of 12 months (1-110), the 2-year overall survival rates were 55% and 30% in negative and positive p53, respectively (P = 0.084). Also, the 2-year overall survival rates were 45% and 53% in negative and positive UHRF-1, respectively (P = 0.132).
  
  
  CONCLUSIONS
  According to this study, UHRF-1 and p53 were not prognostic factors for gastric cancer, whereas they may have a diagnostic value for differentiating between gastric cancer and gastritis.
authors.affiliation: Department of Medical Oncology, Cumhuriyet University School of Medicine, Sivas, Turkey.
authors.forename: Nalan A
authors.initials: NA
authors.lastname: Babacan
authors.forename: Hatice Reyhan
authors.initials: HR
authors.lastname: Egilmez
authors.forename: Birsen
authors.initials: B
authors.lastname: Yücel
authors.forename: Parlak
authors.initials: P
authors.lastname: Ilknur
authors.forename: Mehmet Metin
authors.initials: MM
authors.lastname: Seker
authors.forename: Turgut
authors.initials: T
authors.lastname: Kacan
authors.forename: Aykut
authors.initials: A
authors.lastname: Bahceci
authors.forename: Sener
authors.initials: S
authors.lastname: Cihan
authors.forename: Bülent
authors.initials: B
authors.lastname: Akinci
authors.forename: Berna
authors.initials: B
authors.lastname: Eriten
authors.forename: Saadettin
authors.initials: S
authors.lastname: Kilickap
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D022762:CCAAT-Enhancer-Binding Proteins / Q000096:biosynthesis*; D005260:Female; D005756:Gastritis / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology*; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*; D044767:Ubiquitin-Protein Ligases; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D022762:CCAAT-Enhancer-Binding Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C406364:UHRF1 protein, human; D044767:Ubiquitin-Protein Ligases
references.citation: Ann Oncol. 2008 Sep;19(9):1523-9
references.pmid: 18441328
references.citation: Gastric Cancer. 1998 Mar;1(2):125-133
references.pmid: 11957056
references.citation: Br J Cancer. 1999 Mar;79(7-8):1255-61
references.pmid: 10098768
references.citation: Br J Cancer. 2004 Jan 12;90(1):206-15
references.pmid: 14710231
references.citation: Br J Cancer. 1993 Mar;67(3):589-93
references.pmid: 8439509
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Epigenomics. 2012 Jun;4(3):279-94
references.pmid: 22690664
references.citation: Oncol Lett. 2013 Nov;6(5):1277-1284
references.pmid: 24179508
references.citation: Br J Cancer. 2009 Jul 7;101(1):98-105
references.pmid: 19491893
references.citation: N Engl J Med. 2008 Mar 13;358(11):1148-59
references.pmid: 18337604
references.citation: Oncogene. 2012 Nov 15;31(46):4878-87
references.pmid: 22330138
references.citation: Hum Pathol. 2005 Oct;36(10):1101-7
references.pmid: 16226110
references.citation: Gastric Cancer. 2005;8(2):86-94
references.pmid: 15864715
references.citation: Gastric Cancer. 2007;10(2):112-6
references.pmid: 17577621
references.citation: Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9
references.pmid: 17613547
references.citation: Am J Clin Pathol. 1994 Feb;101(2):177-80
references.pmid: 8116572
references.citation: Br J Cancer. 1992 Sep;66(3):558-62
references.pmid: 1520594
references.citation: Biochem Pharmacol. 2009 Nov 15;78(10):1279-88
references.pmid: 19501055
references.citation: Am J Surg Pathol. 1994 Dec;18(12):1247-53
references.pmid: 7977948
references.citation: FASEB J. 2013 Dec;27(12):4929-39
references.pmid: 23982143
references.citation: Pharmacol Ther. 2007 Sep;115(3):419-34
references.pmid: 17658611
references.citation: Cancer. 1995 Sep 1;76(5):720-6
references.pmid: 8625172
references.citation: World J Gastroenterol. 2013 Feb 28;19(8):1182-92
references.pmid: 23482412
references.citation: Br J Cancer. 2010 Jul 13;103(2):217-22
references.pmid: 20517312
references.citation: Gastroenterology. 2005 Nov;129(5):1454-63
references.pmid: 16285947
references.citation: Nucleic Acids Res. 2009 Feb;37(2):493-505
references.pmid: 19056828
references.citation: Histopathology. 2004 Apr;44(4):323-31
references.pmid: 15049897
references.citation: J Clin Oncol. 2005 Jan 10;23(2):392-403
references.pmid: 15637401
references.citation: Cancer Sci. 2013 Feb;104(2):194-9
references.pmid: 23107467